Sarepta Therapeutics Statistics

Total Valuation

LON:0L35 has a market cap or net worth of GBP 4.70 billion. The enterprise value is 4.70 billion.

Market Cap	4.70B
Enterprise Value	4.70B

Important Dates

The last earnings date was Monday, May 5, 2025.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+16.75%
Shares Change (QoQ)	+7.99%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.85M

Valuation Ratios

The trailing PE ratio is 25.04.

PE Ratio	25.04
Forward PE	n/a
PS Ratio	3.10
PB Ratio	3.85
P/TBV Ratio	3.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.37, with an EV/FCF ratio of -17.15.

EV / Earnings	24.99
EV / Sales	3.28
EV / EBITDA	17.37
EV / EBIT	28.63
EV / FCF	-17.15

Financial Position

The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.88.

Current Ratio	4.20
Quick Ratio	2.74
Debt / Equity	0.88
Debt / EBITDA	3.74
Debt / FCF	-3.92
Interest Coverage	11.86

Financial Efficiency

Return on equity (ROE) is 19.71% and return on invested capital (ROIC) is 5.34%.

Return on Equity (ROE)	19.71%
Return on Assets (ROA)	3.77%
Return on Invested Capital (ROIC)	5.34%
Return on Capital Employed (ROCE)	6.75%
Revenue Per Employee	1.11M
Profits Per Employee	136,955
Employee Count	1,372
Asset Turnover	0.53
Inventory Turnover	2.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -52.13% in the last 52 weeks. The beta is 0.92, so LON:0L35's price volatility has been similar to the market average.

Beta (5Y)	0.92
52-Week Price Change	-52.13%
50-Day Moving Average	77.32
200-Day Moving Average	113.86
Relative Strength Index (RSI)	47.68
Average Volume (20 Days)	1,305

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.29

Income Statement

In the last 12 months, LON:0L35 had revenue of GBP 1.52 billion and earned 187.90 million in profits. Earnings per share was 1.87.

Revenue	1.52B
Gross Profit	621.73M
Operating Income	174.20M
Pretax Income	208.30M
Net Income	187.90M
EBITDA	204.33M
EBIT	174.20M
Earnings Per Share (EPS)	1.87

Full Income Statement

Balance Sheet

The company has 1.08 billion in cash and 1.07 billion in debt, giving a net cash position of 9.52 million.

Cash & Cash Equivalents	1.08B
Total Debt	1.07B
Net Cash	9.52M
Net Cash Per Share	n/a
Equity (Book Value)	1.22B
Book Value Per Share	12.59
Working Capital	1.87B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -164.38 million and capital expenditures -109.40 million, giving a free cash flow of -273.77 million.

Operating Cash Flow	-164.38M
Capital Expenditures	-109.40M
Free Cash Flow	-273.77M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 40.92%, with operating and profit margins of 11.47% and 12.37%.

Gross Margin	40.92%
Operating Margin	11.47%
Pretax Margin	13.71%
Profit Margin	12.37%
EBITDA Margin	13.45%
EBIT Margin	11.47%
FCF Margin	n/a

Dividends & Yields

LON:0L35 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.75%
Shareholder Yield	-16.75%
Earnings Yield	3.99%
FCF Yield	-5.82%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0L35 has an Altman Z-Score of 2.87. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.87
Piotroski F-Score	n/a